Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAVEN 1: Emicizumab Prophylaxis in Hemophilia A with Inhibitors
NCT02622321Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2015
- Primary completion
- Oct 2016
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of emicizumab in hemophilia A (4 arms), sponsored by Roche. Primary endpoint: Model-Based Annualized Bleed Rate for Treated Bleeds at 24 weeks. Started Nov 2015; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02622321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02622321.